Transforming growth factor β signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition

Cancer Research

Volumn 62, Issue 10, 2002, Pages 2778-2790

  Parekh, Trilok V ^a   Gama, Patricia ^a,d   Wen, Xie ^c   Demopoulos, Rita ^a   Munger, John S ^a   Carcangiu, Maria Luisa ^b,e   Reiss, Michael ^c   Gold, Leslie I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e Instituto Tumori   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADULT; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIUM CARCINOMA; FEMALE; FRAMESHIFT MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ADULT; CELL DIVISION; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FRAMESHIFT MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0037092964     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Endometrial cancer: Incidence, prognostic factors, diagnosis, and treatment
2. Loss of growth regulation by transforming growth factor-β (TGF-β) in human cancers: Studies on endometrial carcinoma
3. Tamoxifen and endometrial cancer: Tamoxifen effects on the human female genital tract
4. The role for transforming growth factor-β (TGF-β) in human cancer
5. TGFβ signaling in growth control, cancer, and heritable disorders
6. Transforming growth factor-β negatively modulates proliferation and c-fos expression of the human endometrial adenocarcinoma cell line HEC-1-A
7. Expression of transforming growth factor β 1 by human endometrial carcinoma cell lines: Inverse correlation with effects on growth rate and morphology
8. TGF-β signalling from cell membrane to nucleus through SMAD proteins
9. Development of TGF-β resistance during malignant progression
10. TGF-β and cancer
11. Structural insights on Smad function in TGFβ signaling
12. Induction of transforming growth factor-β receptor type II expression in estrogen receptor-positive breast cancer cells through SPI activation by 5-aza-2′-deoxycytidine
13. Latent transforming growth factor-β: Structural features and mechanisms of activation
14. The mechanism for the activation of latent TGF-β during co-culture of endothelial cells and smooth muscle cells: Cell-type specific targeting of latent TGF-β to smooth muscle cells
15. Extracellular matrix-associated transforming growth factor-β: Role in cancer cell growth and invasion
16. The integrin α v β 6 binds and activates latent TGF β 1: A mechanism for regulating pulmonary inflammation and fibrosis
17. Thrombospondin-1 is a major activator of TGF-β1 in vivo
18. TGF-β receptors and signaling mechanisms
19. Determinants of specificity in TGF-β signal transduction
20. Smads: Transcriptional activators of TGF-β responses
21. TGF-β receptor-mediated signaling through Smad2, Smad3 and Smad4
22. Transforming growth factor-β induces formation of a dithiothreitol-resistant type I/type II receptor complex in live cells
23. Regulation of Smad signaling by protein associations and signaling crosstalk
24. Moses JNK signaling in transforming growth factor-β-mediated transcription
25. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF
26. Role of Ras and Mapks in TGFβ signaling
27. Genetic programs of epithelial cell plasticity directed by transforming growth factor-β
28. Controlling TGF-β signaling
29. Can't get no SMADisfaction: Smad proteins as positive and negative regulators of TGF-β family signals
30. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members
31. Suppression of keratinocyte growth and differentiation by transforming growth factor β1 involves multiple signaling pathways
32. Moses Smad7 synergize in the inhibition of transforming growth factor β signaling
33. Kips off to Myc: Implications for TGF β signaling
34. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15
35. Repression of p15INK4b expression by Myc through association with Miz-1
36. Transforming growth factor-β in benign and malignant prostate
37. Regulation of immune responses by TGF-β
38. TGF β-1 regulation of VEGF production by breast cancer cells
39. Transforming growth factor β 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane
40. TGF-β signaling and cancer: Structural and functional consequences of mutations in Smads
41. Transforming growth factor β type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer
42. Sp3 is a transcriptional repressor of transforming growth factor-β receptors
43. Functional characterization of transforming growth factor β type II receptor mutants in human cancer
44. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis
45. Hyperplasia and carcinoma of the endometrium
46. Cultured endometrial cancer cells exhibit autocrine growth factor stimulation that is not observed in cultured normal endometrial cells
47. Growth and phenotypic characterization of porcine coronary artery smooth muscle cells
48. Techniques for monitoring cell cycle phases
49. Transforming growth factor β mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium
50. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct
51. Two distinct tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line
52. Type I (RI) and type II (RI) receptors for transforming growth factor-β isoforms are expressed subsequent to transforming growth factor-β ligands during excisional wound repair
53. Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: Evidence for paracrine and autocrine action
54. Smad protein expression and activation in transforming growth factor-β refractory human squamous cell carcinoma cells
55. Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition
56. Increased degradation of p27kipI via the ubiquitin-proteasome pathway in endometrial carcinoma is associated with loss of growth inhibition by TGF-β
57. Tumor suppressor activity of the TGF-β pathway in human cancers
58. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
59. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome - A tissue microarray study
60. Growth factors and their receptors in pancreatic cancer
61. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer
62. Smad7 mediates apoptosis induced by transforming growth factor β in prostatic carcinoma cells
63. Positive and negative regulation of TGF-β signaling
64. Synergism between transcription factors TFE3 and Smad3 in transforming growth factor-βinduced transcription of the Smad7 gene
65. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
66. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis
67. Smad3 mutant mice develop metastatic colorectal cancer
68. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice
69. Smad2, Smad3 and Smad4 cooperate with Spl to induce pl5(Ink4B) transcription in response to TGF-β
70. Loss of Smad2 activation correlates with poor outcome in human colon cancer - A tissue mivroarray analysis
71. Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer
72. Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer
73. Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency
74. Regulation of transforming growth factor-β type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues
75. Ubiquitin-dependent degradation of TGF-β-activated smad2
76. The Smad pathway
77. Ligand-dependent degradation of smad3 by a ubiquitin ligase complex of roc I and associated proteins
78. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer
79. Microsatellite instability and mutated type II transforming growth factor-β receptor gene in gliomas
80. Mutational analysis of transforming growth factor β receptor type II and DNA mismatch repair genes in sporadic endometrial carcinomas with microsatellite instability
81. Causes and consequences of microsatellite instability in endometrial carcinoma
82. Genetic alterations in the transforming growth factor receptor complex in sporadic endometrial carcinoma
83. Transforming growth factor-β receptor type I gene is frequently mutated in ovarian carcinomas
84. Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer
85. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients
86. Expression of TGF-β isoforms. TGF-β receptors, and SMAD molecules at different stages of human glioma
87. Ovarian carcinoma cell cultures are resistant to TGF-β1-mediated growth inhibition despite expression of functional receptors
88. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells
89. Expression profile of agonistic Smads in human breast cancer cells: Absence of regulation by estrogens
90. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor β growth arrest program